AR086538A1 - COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE - Google Patents

COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE

Info

Publication number
AR086538A1
AR086538A1 ARP120101825A ARP120101825A AR086538A1 AR 086538 A1 AR086538 A1 AR 086538A1 AR P120101825 A ARP120101825 A AR P120101825A AR P120101825 A ARP120101825 A AR P120101825A AR 086538 A1 AR086538 A1 AR 086538A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
cycloalkyl
alkoxy
compounds
Prior art date
Application number
ARP120101825A
Other languages
English (en)
Inventor
Lorin A Thompson Iii
Jianliang Shi
Yong Wu
Lawrence R Jin-Marcin
Ramkumar Rajamani
Mendi A Higgins
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR086538A1 publication Critical patent/AR086538A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/041,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/081,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos de la fórmula (1), que incluyen sales de estos aceptables desde el punto de vista farmacéutico, se indican en la presente, en donde X se selecciona del grupo de CH2, O y NR2; m = 0 ó 1; R1 se selecciona, en cada caso, del grupo de halógeno, hidroxi, amino, alquilamino C1-4, dialquilamino C1-4, haloalquilo C1-4, CN, alquilo C1-6 o cicloalquilo, alcoxi C1-6 y alquinilo C2-4; L es un enlace, -NHCO-, -NH- o L y Z juntos pueden estar ausentes; Z es un grupo arilo C6-10 o un grupo heterocíclico de 5 - 10 miembros que también se puede sustituir con 0 - 3 sustituyentes seleccionados del grupo de halógeno, haloalcoxi C1-4, 4-metoxifenilo, hidroxi, amino, alquilamino C1-4, dialquilamino C1-4, haloalquilo C1-4, CN, alquilo C1-6 o cicloalquilo, alcoxi C1-6 y alquinilo C2-4; R2 se selecciona del grupo de hidrógeno, bencilo, alquilo C1-6 o cicloalquilo, alcoxi C1-6, acetilo y metansulfonilo; y R3, R4 y R5 se seleccionan, independientemente, de hidrógeno o alquilo C1-4. Composiciones farmacéuticas y usos.
ARP120101825A 2011-05-24 2012-05-23 COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE AR086538A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489438P 2011-05-24 2011-05-24
US13/477,143 US8604024B2 (en) 2011-05-24 2012-05-22 Compounds for the reduction of beta-amyloid production

Publications (1)

Publication Number Publication Date
AR086538A1 true AR086538A1 (es) 2014-01-08

Family

ID=46201836

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101825A AR086538A1 (es) 2011-05-24 2012-05-23 COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE

Country Status (4)

Country Link
US (1) US8604024B2 (es)
AR (1) AR086538A1 (es)
TW (1) TW201300381A (es)
WO (1) WO2012162330A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
RU2476430C2 (ru) 2007-04-24 2013-02-27 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина, замещенные циклической группой
EP2305672B1 (en) 2008-06-13 2019-03-27 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
WO2012057248A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 ナフチリジン誘導体
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
WO2014120658A1 (en) 2013-01-29 2014-08-07 Amgen Inc. Fused multicyclic 3-amino-5,6-dihydro-2h-1,4-thiazine derivatives and their use as beta-secretase inhibitors
MX366855B (es) 2013-03-01 2019-07-26 Amgen Inc Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
CN105164121A (zh) 2013-03-08 2015-12-16 美国安进公司 作为β分泌酶抑制剂的全氟化环丙基稠合的1,3-噁嗪-2-胺化合物以及其使用方法
WO2015017407A1 (en) 2013-07-30 2015-02-05 Amgen Inc. Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta- secretase
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
CN106795147B (zh) 2014-08-08 2020-09-22 美国安进公司 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法
WO2016053828A1 (en) 2014-10-03 2016-04-07 Merck Sharp & Dohme Corp. C5-c6-fused tricyclic iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US10246429B2 (en) 2015-08-06 2019-04-02 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US10889581B2 (en) 2016-12-15 2021-01-12 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
ES2910791T3 (es) 2016-12-15 2022-05-13 Amgen Inc Derivados de tiazina como inhibidores de beta-secretasa y métodos de uso
US11548903B2 (en) 2016-12-15 2023-01-10 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
MX2019007101A (es) 2016-12-15 2019-12-16 Amgen Inc Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
EP3555086B1 (en) 2016-12-15 2021-09-01 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
TW201016708A (en) 2008-09-30 2010-05-01 Eisai R&D Man Co Ltd Novel fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer

Also Published As

Publication number Publication date
US20130131051A1 (en) 2013-05-23
TW201300381A (zh) 2013-01-01
WO2012162330A1 (en) 2012-11-29
US8604024B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
AR086539A1 (es) COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
CU20080165A7 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR092568A1 (es) Derivados triciclicos de quinolinas y de quinoxalinas
AR087311A1 (es) Quinolinas sustituidas y su uso como medicamentos
AR075892A1 (es) Derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
CR20140294A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
PE20160992A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk)
AR077215A1 (es) Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos
ES2526902T3 (es) Procesos de producción de inhibidores de la girasa y topoisomerasa IV
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AR087487A1 (es) Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak)
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
HN2011003482A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR085236A1 (es) Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d

Legal Events

Date Code Title Description
FA Abandonment or withdrawal